GlassScriptPhysician profile
Mark Deguenther
NPI 1609849488
$2,532.98
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $365 · 2020: $1,197 · 2021: $602 · 2022: $340 · 2023: $28.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $28.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $28.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $823.20 | 2020-2021 | |
| Astellas Pharma US INC | $207.22 | 2019-2023 | Myrbetriq |
| Baxter Healthcare | $185.97 | 2020 | |
| Endo Pharmaceuticals INC. | $148.92 | 2019-2022 | |
| Allergan, INC. | $142.41 | 2020-2021 | |
| Urogen Pharma, INC. | $132.50 | 2021-2022 | |
| Urovant Sciences INC | $119.61 | 2021-2022 | |
| Janssen Biotech, INC. | $79.35 | 2021 | |
| Medtronic USA, INC. | $70.41 | 2019-2020 | |
| Abbott Laboratories | $50.68 | 2021 | |
| Travere Therapeutics, INC. | $49.18 | 2019-2021 | |
| Myovant Sciences INC. | $48.42 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $47.03 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $41.05 | 2019-2022 | |
| Dendreon Pharmaceuticals LLC | $37.04 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Progenics Pharmaceuticals, INC. | $33.82 | 2022 | |
| Neotract INC. | $32.07 | 2019 | |
| Medtronic, INC. | $31.74 | 2021 | |
| Abbvie INC. | $31.63 | 2019-2022 | |
| Aytu Biopharma, INC. | $30.65 | 2019 | |
| Coloplast Corp | $29.65 | 2019-2020 | |
| 180 Medical, INC. | $29.05 | 2021 | |
| Blue Earth Diagnostics | $24.31 | 2022 | |
| Merck Sharp & Dohme LLC | $24.28 | 2021 | |
| Pfizer INC. | $19.35 | 2022 | |
| Convatec INC. | $18.86 | 2021 | |
| Mckesson Patient Care Solutions INC. | $16.90 | 2019 | |
| Metuchen Pharmaceuticals | $13.92 | 2020 | |
| Axonics, INC. | $13.76 | 2023 | Axonics |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Deguenther listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.